过敏性紫癜性肾炎 中国就医指南

Henoch-Schönlein purpura nephritis (HSPN) is a systemic small-vessel vasculitis characterized by immunoglobulin A (IgA)-dominant immune complex deposition in the glomeruli, leading to renal inflammation and injury. It represents the renal manifestation of Henoch-Schönlein purpura (HSP), a childhood-predominant systemic vasculitis that also involves skin (palpable purpura), joints (arthralgia/arthritis), gastrointestinal tract (abdominal pain, bleeding), and kidneys. While HSP typically resolves spontaneously in most children, renal involvement—ranging from isolated microscopic hematuria to nephrotic-range proteinuria, hypertension, and rapidly progressive glomerulonephritis—defines HSPN and carries significant long-term implications. Pathogenesis centers on aberrant mucosal IgA1 production, defective galactosylation of the IgA1 hinge region, formation of pathogenic IgA1-containing immune complexes, and their mesangial deposition, triggering complement activation (mainly lectin and alternative pathways), inflammatory cell infiltration, and subsequent glomerular damage. Genetic susceptibility (e.g., polymorphisms in TNFSF13, CFH, and HLA loci), preceding upper respiratory or gastrointestinal infections (often streptococcal or viral), and environmental triggers contribute to dysregulated mucosal immunity. Epidemiologically, HSP is the most common systemic vasculitis in children, with an incidence of 10–20 per 100,000 children annually; approximately 30–50% develop urinary abnormalities, and 20–40% of those progress to clinically significant HSPN. Adults account for <10% of cases but tend to present with more severe renal disease, higher rates of crescentic glomerulonephritis, and poorer renal outcomes. Risk factors for progression include older age at onset (>8 years in children, any age in adults), persistent heavy proteinuria (>1 g/day), hypertension, impaired eGFR at diagnosis, and histopathological severity (e.g., >50% crescents, interstitial fibrosis/tubular atrophy on biopsy). Quality of life impact is substantial: pediatric patients may experience school absenteeism, activity restrictions, anxiety about relapse or kidney failure, and treatment-related side effects (e.g., corticosteroid-induced weight gain, mood changes, growth delay). Adults often face occupational disruption, chronic fatigue, dietary and fluid restrictions, and psychosocial stress related to uncertainty about long-term renal prognosis—including risks of end-stage kidney disease (ESKD) in 1–5% of pediatric and up to 15% of adult cases over 10–20 years. Early recognition, risk stratification via clinical and histologic assessment, and individualized immunomodulatory therapy are critical to preserving renal function and optimizing long-term quality of life.

# 过敏性紫癜性肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：轻中度蛋白尿（<1.0 g/d）、镜下血尿、eGFR正常或轻度下降（≥60 mL/min/1.73m²）、无新月体形成者。

• •基础治疗：避免过敏原、优质低蛋白饮食、ACEI/ARB（如缬沙坦）——年药费：1200–3600元
• •糖皮质激素（泼尼松起始0.8–1.0 mg/kg/d，8–12周渐减）——3个月药费+随访：4500–9800元（含肝肾功能、尿常规、24h尿蛋白定量×4次）
• •免疫抑制剂（霉酚酸酯/环磷酰胺）——6个月方案总费用：18,000–32,000元（含血药浓度监测、骨髓象、感染筛查等）

二、肾脏穿刺活检（核心诊断与分型依据）

适用条件：蛋白尿≥1.0 g/d、肾功能进行性下降、病理分型不明需精准干预者。

• •术前检查（凝血四项、乙肝丙肝、eGFR、双肾超声）：1280–1650元
• •B超引导下经皮肾活检+光镜/免疫荧光/电镜：4200–6500元（含病理分级报告）

三、特殊复杂/耐药/晚期方案

• •重症新月体肾炎（>50%新月体）：甲泼尼龙冲击+环磷酰胺静脉序贯——首月住院+治疗费：35,000–62,000元
• •终末期肾病（eGFR<15）：转入CKD-MBD管理，启动透析准备——年度综合管理费（含营养支持、贫血纠正、钙磷调控）：48,000–85,000元

四、方案快速选择指南

• •预算≤1万元/年：ACEI/ARB+生活方式干预（限轻症）
• •预算2–5万元/年：激素±霉酚酸酯，配合规范随访
• •急进性肾衰/新月体＞50%：立即启动冲击治疗+肾活检，优选三甲肾内科住院路径